Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study
Titel:
Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study
Auteur:
Bendell, Johanna C. Tournigand, Christophe Swieboda-Sadlej, Anna Barone, Carlo Wainberg, Zev A. Kim, Jong Gwang Pericay, Carles Pastorelli, Davide Tarazi, Jamal Rosbrook, Brad Bloom, Joanna Ricart, Alejandro D. Kim, Sinil Sobrero, Alberto F.